The study team used RNA sequencing to compare ovarian cancer cells exposed to cisplatin (CDDP), nelfinavir (NFV), or their combination. Short treatments produced measurable differences. RNA data indicated enrichment of interferon-associated transcripts, cytoplasmic DNA sensing modules, inflammatory chemokine programs, and antigen-presentation pathways when NFV was present. The combination of NFV plus CDDP generated larger pathway-level signals than either agent alone, according to the authors. These pathway changes point to an inflammatory transcriptional state that coincides with agents known to cause cellular damage and immune-related signaling.
The authors described this transcriptional shift as linked to downstream events that would increase exposure of nucleic acids to cytosolic sensors. Cells treated with NFV-containing regimens showed alterations consistent with nuclear envelope perturbation and extranuclear DNA accumulation. The RNA-seq results therefore framed subsequent biochemical and cell-biological assays the team performed to identify a mechanistic chain from DNA leakage to innate immune pathway activation.
The investigators reported reduced abundance of mature Lamin A after NFV alone and after NFV combined with CDDP. Lamin A loss can destabilize nuclear architecture. In this dataset, Lamin A reduction accompanied accumulation of extranuclear double-stranded DNA. The authors used cytosolic fractionation followed by droplet digital PCR and detected increased cytosolic TP53 DNA; levels were highest after the combined NFV+CDDP treatment. The source did not report precise cell-line dosing regimens or time points in the abstract; those methodological specifics are not available in the provided text.
Biochemical signaling data aligned with the nucleic-acid findings. The study team observed increased phosphorylation of STING and TBK1 in cells receiving combined therapy. Those phosphorylation events are consistent with activation of the cGAS–STING–TBK1 axis, which senses cytosolic DNA and drives type I interferon production in many systems. The authors therefore linked nuclear envelope disruption and cytosolic DNA accumulation to engagement of an innate DNA-sensing cascade in ovarian cancer cells following NFV-containing treatments.
Beyond intracellular signaling, the combination promoted extracellular release of mediators associated with inflammatory responses and immunogenic cell death. The investigators measured increased levels of HMGB1, IL18, and IFNbeta after combined CDDP plus NFV treatment. Those factors are often cited as hallmarks or contributors to ICD by attracting and activating antigen-presenting cells; the authors used these readouts to argue that the cell death induced by the combination has immunogenic properties rather than being purely accidental necrosis.
To test biological relevance, the group performed a vaccination experiment using the murine ID8 ovarian cancer model. Mice vaccinated with ID8 cells killed by CDDP+NFV showed protection against subsequent challenge with live ID8 cells, with reduced tumor incidence and lower tumor burden compared with controls. The authors contrasted this outcome with ID8 cells killed by freeze–thaw necrosis, which did not confer protection. These in vivo data support the claim that combined NFV and cisplatin treatment can convert killed tumor cells into an immunogenic vaccine-like material in this preclinical model.
This work is presented as a preprint and the experiments are preclinical. The source did not report clinical dosing, safety or toxicity data for combining nelfinavir with cisplatin in patients; those items remain unaddressed in the abstract. The animal results derive from a vaccination challenge model (ID8 cells in immunocompetent female mice); extrapolation to humans therefore requires caution. The authors recommended further investigation of NFV as a repurposed partner for platinum-based chemotherapy and the potential combination with immunotherapy, but regulatory milestones, trial design, and human tolerability were not described in the available text.
Key unanswered questions recorded by the investigators include optimal scheduling and dosing for combination therapy, whether NFV enhances ICD across diverse ovarian cancer subtypes, and how this approach would integrate with existing checkpoint inhibitors in patients. Those remain to be tested in additional preclinical work and in carefully designed clinical trials before any change in patient care can be considered.